EANS-News: AGENNIX AG /dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Planegg/Munich (euro adhoc) - Planegg/Munich (Germany), November 4,
2010 - Agennix AG (Frankfurt Stock Exchange (Prime Standard):
AGX/ISIN DE000A1A6XX4) was informed yesterday that the German Federal
Financial Supervisory Authority (Bundesanstalt fuer
Finanzdienstleistungsaufsicht) (BaFin) has yesterday granted the
Company´s largest shareholder, dievini Hopp BioTech holding GmbH &
Co. KG ("dievini"), and certain other persons and legal entities to
whom dievini´s share ownership is attributed, an exemption from the
obligations pursuant to Section 35 of the German Takeover Act to
publish the acquisition of control, to provide BaFin an offer
document, and to publish a mandatory tender offer to the other
shareholders of Agennix AG in connection with the capital increase of
the Company completed in October 2010.

As a result of their participation in the capital increase completed
on October 4, 2010, dievini and certain other persons and legal
entities to whom dievini´s share ownership is attributed, acquired
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act and would have been required to make a mandatory tender
offer to the other shareholders of Agennix had the exemption not been
granted.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, an oral therapy that has
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing, and a topical gel form of talactoferrin
for diabetic foot ulcers. Agennix´s registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG

Investor Relations & Corporate Communications

Phone: +49 (0)89 8565 2693

ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade